methyl-(4-methyl-cyclohex-3-enyl)-ether | 108420-43-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl-(4-methyl-cyclohex-3-enyl)-ether
• 英文别名: Methyl-(4-methyl-cyclohex-3-enyl)-aether；Methyl 4-methyl-3-cyclohexen-1-yl ether；4-methoxy-1-methylcyclohexene
• CAS: 108420-43-5
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: ACCCOWUHBNTLLK-UHFFFAOYSA-N

物化性质

• 沸点：
  91-92 °C(Press: 80 Torr)
• 密度：
  0.88±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-methoxy-1-methylcyclohexan-1-ol 在 potassium hydrogensulfate 作用下， 生成 methyl-(4-methyl-cyclohex-3-enyl)-ether
  参考文献：
  名称：

  Psychometric Properties of the Observer Alexithymia Scale in a Clinical Sample

  摘要：

  The purpose of this study was to evaluate the psychometric properties of the Observer Alexithymia Scale (OAS; Haviland, Warren, & Riggs, 2000) in a clinical setting Clinical and counseling psychologists used the OAS to rate outpatients (n = 192) with various Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, 1994) diagnoses. Reliability and validity data are similar to the initial nonclinical data (n = 819): OAS scores are reliable (coefficient alpha = .90), and the five-factor structure-Distant, Uninsightful, Somatizing, Humorless, and Ri.-id-was confirmed. Moreover, the OAS does a relatively good job of differentiating clinical from nonclinical cases. The OAS is psychometrically sound, and it appears to be a useful tool for collecting and evaluating observer data on the clinically relevant, everyday expressions of alexithymia.

  DOI：

  10.1207/s15327752jpa7701_12

文献信息

• Ligand effect in the Rh-NP catalysed partial hydrogenation of substituted arenes
  作者：Jessica Llop Castelbou、Aitor Gual、Elisabet Mercadé、Carmen Claver、Cyril Godard

  DOI：10.1039/c3cy00388d

  日期：——

  phosphine and phosphite ligands I–IV were synthesised, characterised and applied as catalysts in the partial hydrogenation of substituted arenes. In the case of disubstituted arenes, selectivities for the corresponding cyclohexene derivatives of up to 39% were achieved at ca. 40% conversion. The effect of parameters such as temperature and pressure was also examined. In the hydrogenation of styrene, very

  合成了由单和双齿膦和亚磷酸酯配体I-IV稳定的Rh纳米粒子Rh1-Rh4，对其进行了表征和应用，将其用作取代芳烃的部分加氢反应的催化剂。在双取代的芳烃的情况下，在约100 ℃下对相应的环己烯衍生物的选择性高达39％。40％的转化率。还检查了参数（例如温度和压力）的影响。在加氢中苯乙烯，具有很高的选择性 乙苯TOF值达到约。23 500小时-1。所有这些结果表明，小的Rh-的NP的催化性能可以通过稳定剂的合适的选择来调制。
• PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20110160182A1

  公开（公告）日：2011-06-30

  Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明提供了吡嗪化合物、含有它们的组合物以及制备这些化合物的方法。本发明还提供了治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症、非胰岛素依赖性糖尿病、精神分裂症、双相障碍、强迫症等。
• ANTIDEPRESSANT
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1481679B1

  公开（公告）日：2010-08-25
• US8247418B2
  申请人：——

  公开号：US8247418B2

  公开（公告）日：2012-08-21
• US8329700B2
  申请人：——

  公开号：US8329700B2

  公开（公告）日：2012-12-11

表征谱图